摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-氰基亚苄基)肼-1-硫代甲酰胺 | 22043-24-9

中文名称
2-(4-氰基亚苄基)肼-1-硫代甲酰胺
中文别名
——
英文名称
4-thiosemicarbazonomethyl-benzonitrile
英文别名
4-Thiosemicarbazonomethyl-benzonitril;[(4-Cyanophenyl)methylideneamino]thiourea
2-(4-氰基亚苄基)肼-1-硫代甲酰胺化学式
CAS
22043-24-9
化学式
C9H8N4S
mdl
MFCD00173811
分子量
204.255
InChiKey
XQPDUVUNLGKRGX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    243 °C

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    106
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S36/37
  • 危险类别码:
    R20/21/22

SDS

SDS:ea9c67aaf55eaf4a00e03ba6dcb5bce9
查看
Name: 2-(4-Cyanobenzylidene)hydrazine-1-carbothioamide 97% Material Safety Data Sheet
Synonym: 1-(4-Cyanobenzylidene)thiosemicarbazid
CAS: 22043-24-9
Section 1 - Chemical Product MSDS Name:2-(4-Cyanobenzylidene)hydrazine-1-carbothioamide 97% Material Safety Data Sheet
Synonym:1-(4-Cyanobenzylidene)thiosemicarbazid

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
22043-24-9 2-(4-Cyanobenzylidene)hydrazine-1-carb 97% unlisted
Hazard Symbols: XN
Risk Phrases: 20/21/22

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22043-24-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 243 - 247 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8N4S
Molecular Weight: 204

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases, amines.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22043-24-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(4-Cyanobenzylidene)hydrazine-1-carbothioamide - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 22043-24-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22043-24-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22043-24-9 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Winkelmann; Rolly, Arzneimittel-Forschung/Drug Research, 1972, vol. 22, # 10, p. 1704 - 1713
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    新型噻唑席夫碱衍生物的合成、抗菌和抗氧化评估与计算机模拟研究
    摘要:
    合成了一系列 19 种噻唑席夫碱衍生物2a-2s(方案 1)并通过光谱分析(IR、1 H NMR 和 HRMS)阐明。对它们对两种革兰氏阳性菌、两种革兰氏阴性菌和两种真菌菌株的抗菌活性的评估表明,与标准的环丙沙星和咪康唑在圆盘扩散技术中相比,某些化合物显示出中等的抗菌活性。 在 DPPH 自由基清除试验中, 与标准抗坏血酸 (IC 50 = 27.34 ± 1.86 µg/mL)相比,化合物2a显示出非常强的抗氧化功效 (IC 50 = 3.52 ± 0.86 µg/mL) 。化合物2j、2k和2m在该测定中也显示出显着的抗氧化活性。计算机分析预测合成的化合物遵循 Lipinski 的五法则和 Veber 法则,只有一个例外。这些化合物显示出良好的药物相似性和药物评分特性。分子对接研究预测合成的噻唑席夫碱衍生物在推定的受体结合位点是可以耐受的。
    DOI:
    10.1016/j.molstruc.2021.131465
点击查看最新优质反应信息

文献信息

  • Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
    作者:Thiago M. de Aquino、Paulo H. B. França、Érica E. E. S. Rodrigues、Igor. J.S. Nascimento、Paulo F. S. Santos-Júnior、Pedro G. V. Aquino、Mariana S. Santos、Aline C. Queiroz、Morgana V. Araújo、Magna S. Alexandre-Moreira、Raiza R. L. Rodrigues、Klinger A. F. Rodrigues、Johnnatan D. Freitas、Jacques Bricard、Mario R. Meneghetti、Jean-Jacques Bourguignon、Martine Schmitt、Edeildo F. da Silva-Júnior、João X. de Araújo-Júnior
    DOI:10.2174/1573406417666210216154428
    日期:2022.2
    Background:

    Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi.

    Objective:

    Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds.

    Method:

    A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software.

    Result:

    The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms.

    Conclusion:

    The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.

    背景:利什曼病是全球性健康问题,在发展中国家高度流行。在该病的四种主要临床形式中,内脏利什曼病是最严重的,95%的病例会致命。由于一线化疗药物的不良副作用和报道的药物耐药性,迫切需要寻找可以替代或补充当前使用的有效药物。氨基胍脒肼酮(AGH)已被探索用于展示多样的生物活性,特别是MGBG的抗利什曼病活性。生物同功异构体硫脲半胱氨酮(TSC)提供类似的生物活性多样性,包括对利什曼病和克氏锥虫的抗原虫效应。 目的:考虑到利什曼病在全球范围内的影响,本研究旨在设计、合成并对L. chagasi阿马斯蒂果虫进行筛选,以及对小型“内部”AGH和TSC衍生物及其结构相关化合物的细胞毒性进行评估。 方法:首先合成了一组AGH(3-7)、TSC(9, 10)和半胱氨酮(11)。随后,设计并制备了不同的半约束类似物,包括噻唑烷(12)、二氢噻嗪(13)、咪唑烷(15)、嘧啶(16, 18)、吲哚烷(19, 20)和苯并三唑环酮(23-25)。所有中间体和目标化合物均以满意的收率获得,并展示了与其结构一致的光谱数据。所有最终化合物均对L. chagasi阿马斯蒂果虫和J774.A1细胞系进行了评估。使用GOLD®软件对其进行了针对巯基还原酶的分子对接。 结果:AGH的3i、4a和5d以及TSC的9i、9k和9o被选为有价值的命中物。这些化合物与五环胺相比具有抗利什曼病活性,IC50值范围从0.6到7.27μM,最大效果高达55.3%,满意的SI值(范围从11到87)。另一方面,大多数结果的半约束类似物被发现具有细胞毒性或具有降低的抗利什曼病活性。总体而言,TSC类比其同功异构AGH类更有前景,而有益的芳香族取代作用在两个系列中并不相似。计算机模拟研究表明这些命中物能够抑制阿马斯蒂果虫的巯基还原酶。 结论:三种AGH和三种TSC的有前景的抗利什曼病活性得到了表征。这些化合物与PTD相比具有抗利什曼病活性,IC50值范围从0.6到7.27μM,SI值满意。正在进行涉及其他利什曼病菌株的进一步药理学评估,这将有助于选择最佳的命中物进行体内实验。
  • Winkelmann; Rolly, Arzneimittel-Forschung/Drug Research, 1972, vol. 22, # 10, p. 1704 - 1713
    作者:Winkelmann、Rolly
    DOI:——
    日期:——
  • Synthesis of 1,2,4-triazoles employing isocyanides
    作者:Pakornwit Sarnpitak、Mikhail Krasavin
    DOI:10.1016/j.tet.2013.01.039
    日期:2013.3
    A conceptually new, two-step synthesis of medicinally important 1,2,4-triazoles from isocyanides and thiosemicarbazones was developed. The method is based on the recently discovered TMSCI-promoted reaction of isocyanides that yields rare N-1,N-3-disubstututed formamidrazones. (C) 2013 Elsevier Ltd. All rights reserved.
  • Synthesis, antimicrobial and antioxidant evaluation with in silico studies of new thiazole Schiff base derivatives
    作者:Md. Shahazada Shah、Mohammad Mostafizur Rahman、Md. Din Islam、Abdullah Al-Macktuf、Junaid Uddin Ahmed、Hiroshi Nishino、Md. Aminul Haque
    DOI:10.1016/j.molstruc.2021.131465
    日期:2022.1
    A series of nineteen thiazole Schiff base derivatives 2a-2s were synthesized (Scheme 1) and elucidated by spectral analyses (IR, 1H NMR and HRMS). The evaluation of their antimicrobial activities against two gram-positive, two gram-negative, and two fungal strains revealed that some compounds displayed moderate antimicrobial activities compared to standard ciprofloxacin and miconazole in disc diffusion
    合成了一系列 19 种噻唑席夫碱衍生物2a-2s(方案 1)并通过光谱分析(IR、1 H NMR 和 HRMS)阐明。对它们对两种革兰氏阳性菌、两种革兰氏阴性菌和两种真菌菌株的抗菌活性的评估表明,与标准的环丙沙星和咪康唑在圆盘扩散技术中相比,某些化合物显示出中等的抗菌活性。 在 DPPH 自由基清除试验中, 与标准抗坏血酸 (IC 50 = 27.34 ± 1.86 µg/mL)相比,化合物2a显示出非常强的抗氧化功效 (IC 50 = 3.52 ± 0.86 µg/mL) 。化合物2j、2k和2m在该测定中也显示出显着的抗氧化活性。计算机分析预测合成的化合物遵循 Lipinski 的五法则和 Veber 法则,只有一个例外。这些化合物显示出良好的药物相似性和药物评分特性。分子对接研究预测合成的噻唑席夫碱衍生物在推定的受体结合位点是可以耐受的。
  • Synthesis of 2-Amino-1,3,4-oxadiazoles and 2-Amino-1,3,4-thiadiazoles via Sequential Condensation and I<sub>2</sub>-Mediated Oxidative C–O/C–S Bond Formation
    作者:Pengfei Niu、Jinfeng Kang、Xianhai Tian、Lina Song、Hongxu Liu、Jie Wu、Wenquan Yu、Junbiao Chang
    DOI:10.1021/jo502518c
    日期:2015.1.16
    2-Amino-substituted 1,3,4-oxadiazoles and 1,3,4-thiadiazoles were synthesized via condensation of semicarbazide/thiosemicarbazide and the corresponding aldehydes followed by I-2-mediated oxidative C-O/C-S bond formation. This transition-metal-free sequential synthesis process is compatible with aromatic, aliphatic, and cinnamic aldehydes, providing facile access to a variety of diazole derivatives bearing a 2-amino substituent in an efficient and scalable fashion.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐